APA (7th ed.) Citation

B, A., H, P., S, G., I, K., X, L., H, v. d. V., . . . P, M. (2012). Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica, 97(12), 1925. https://doi.org/10.3324/haematol.2012.067793

Chicago Style (17th ed.) Citation

B, Arnulf, et al. "Updated Survival Analysis of a Randomized Phase III Study of Subcutaneous Versus Intravenous Bortezomib in Patients with Relapsed Multiple Myeloma." Haematologica 97, no. 12 (2012): 1925. https://doi.org/10.3324/haematol.2012.067793.

MLA (9th ed.) Citation

B, Arnulf, et al. "Updated Survival Analysis of a Randomized Phase III Study of Subcutaneous Versus Intravenous Bortezomib in Patients with Relapsed Multiple Myeloma." Haematologica, vol. 97, no. 12, 2012, p. 1925, https://doi.org/10.3324/haematol.2012.067793.